| SHARE CAPITAL |
9.
SHARE CAPITAL
The
Company had the following common share transactions for the three months ended March 31, 2023:
SCHEDULE
OF SHARE CAPITAL
| |
|
Three months ended March 31, 2023 |
|
| |
|
# of shares |
|
|
Amount |
|
| Common shares issued for conversion of convertible debt |
|
|
710,807 |
|
|
$ |
1,048,573 |
|
| Common shares issued for compensation |
|
|
155,898 |
|
|
|
105,512 |
|
| Common shares issued for consulting services |
|
|
15,000 |
|
|
|
27,735 |
|
| Common shares issued on conversion of vested prefunded warrants |
|
|
1,637,049 |
|
|
|
2,959,108 |
|
| Total common shares issued |
|
|
2,518,754 |
|
|
$ |
4,140,928 |
|
The
Company had the following common share transactions for the three months ended March 31, 2022:
| |
|
Three months ended March 31, 2022 |
|
| |
|
# of shares |
|
|
Amount |
|
| Common shares issued for consulting services |
|
|
40,997 |
|
|
$ |
88,071 |
|
| Common shares issued for compensation |
|
|
29,317 |
|
|
|
97,121 |
|
| Total common shares issued |
|
|
70,314 |
|
|
$ |
185,192 |
|
Basic
and diluted net loss per share represents the loss attributable to shareholders divided by the weighted average number of shares and
prefunded warrants outstanding during the period on an as converted basis.
Potentially
dilutive securities that are not included in the calculation of diluted net loss per share because their effect is anti-dilutive are
as follows (in common equivalent shares):
SCHEDULE
OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE
| |
|
March 31, 2023
|
|
|
March 31, 2022
|
|
| Warrants |
|
|
12,537,969 |
|
|
|
5,770,262 |
|
| Options |
|
|
1,382,629 |
|
|
|
717,019 |
|
| Convertible debentures |
|
|
11,358,526 |
|
|
|
- |
|
| Total anti-dilutive weighted average shares |
|
|
25,279,124 |
|
|
|
6,487,281 |
|
|